NASDAQ:INO - Inovio Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.34 -0.08 (-2.34 %) (As of 05/20/2019 01:19 AM ET)Previous Close$3.34Today's Range$3.27 - $3.4452-Week Range$3.02 - $6.30Volume1.07 million shsAverage Volume810,120 shsMarket Capitalization$327.42 millionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Receive INO News and Ratings via Email Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INO Previous Symbol CUSIPN/A CIK1055726 Webwww.inovio.com Phone267-440-4200Debt Debt-to-Equity Ratio1.02 Current Ratio4.92 Quick Ratio4.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$30.48 million Price / Sales10.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book4.02Profitability EPS (Most Recent Fiscal Year)($1.05) Net Income$-96,970,000.00 Net Margins-295.24% Return on Equity-97.95% Return on Assets-61.34%Miscellaneous Employees281 Outstanding Shares98,030,000Market Cap$327.42 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions What is Inovio Pharmaceuticals' stock symbol? Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO." When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work? Inovio Pharmaceuticals shares reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals Inc (NASDAQ:INO) announced its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.01. The biopharmaceutical company earned $2.83 million during the quarter, compared to analysts' expectations of $4.44 million. Inovio Pharmaceuticals had a negative return on equity of 97.95% and a negative net margin of 295.24%. View Inovio Pharmaceuticals' Earnings History. When is Inovio Pharmaceuticals' next earnings date? Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Inovio Pharmaceuticals. What price target have analysts set for INO? 4 analysts have issued 1 year price objectives for Inovio Pharmaceuticals' stock. Their predictions range from $3.62 to $13.00. On average, they expect Inovio Pharmaceuticals' share price to reach $8.1550 in the next year. This suggests a possible upside of 144.2% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals. What is the consensus analysts' recommendation for Inovio Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals. What are Wall Street analysts saying about Inovio Pharmaceuticals stock? Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock: 1. HC Wainwright analysts commented, "We note that ASF is highly contagious and the hemorrhagic viral disease is lethal and incurable in domestic and wild pigs. Within the past year, the ASF virus has spread from Europe to Asia countries, including China, Vietnam and Korea. Specifically, over 1M pigs have been culled and slaughtered in 2018, resulting in substantial economic losses. In our view, this partnership could bring Inovio additional upside in the animal health sector without any financial burden. In the wake of this update, we reiterate our Buy rating and $13 price target." (5/16/2019) 2. Maxim Group analysts commented, "Inovio and its collaborators from The Wistar Institute presented positive preclinical data from its novel dBiTE (DNA-Encoded Bi-specific T Cell Engager) program at the American Association for Cancer Research (AACR) annual meeting." (4/3/2019) 3. According to Zacks Investment Research, "Inovio incurred wider-than-expected loss in Q4. Moreover, revenues missed estimates. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares of the company have underperformed the industry so far this year." (3/15/2019) Has Inovio Pharmaceuticals been receiving favorable news coverage? Media stories about INO stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are some of Inovio Pharmaceuticals' key competitors? Some companies that are related to Inovio Pharmaceuticals include K2M Group (KTWO), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX), Tactile Systems Technology (TCMD), Axonics Modulation Technologies (AXNX), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), OraSure Technologies (OSUR), SurModics (SRDX) and Anika Therapeutics (ANIK). What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Anavex Life Sciences (AVXL), Sonoma Pharmaceuticals (SNOA), POET Technologies (POETF), WPX Energy (WPX), Opko Health (OPK), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Micron Technology (MU), Advanced Micro Devices (AMD) and Sangamo Therapeutics (SGMO). Who are Inovio Pharmaceuticals' key executives? Inovio Pharmaceuticals' management team includes the folowing people: Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)Mr. Peter D. Kies, Chief Financial Officer (Age 56)Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52) Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.55%), Wasatch Advisors Inc. (5.99%), Nikko Asset Management Americas Inc. (3.34%), Sumitomo Mitsui Trust Holdings Inc. (3.27%), ARK Investment Management LLC (3.00%) and Dimensional Fund Advisors LP (1.23%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals. Which institutional investors are selling Inovio Pharmaceuticals stock? INO stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Morgan Stanley and Raymond James & Associates. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include Jong Joseph Kim and Peter Kies. View Insider Buying and Selling for Inovio Pharmaceuticals. Which institutional investors are buying Inovio Pharmaceuticals stock? INO stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, Wasatch Advisors Inc., Dimensional Fund Advisors LP, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Inovio Pharmaceuticals. How do I buy shares of Inovio Pharmaceuticals? Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inovio Pharmaceuticals' stock price today? One share of INO stock can currently be purchased for approximately $3.34. How big of a company is Inovio Pharmaceuticals? Inovio Pharmaceuticals has a market capitalization of $327.42 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe. What is Inovio Pharmaceuticals' official website? The official website for Inovio Pharmaceuticals is http://www.inovio.com. How can I contact Inovio Pharmaceuticals? Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected] MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 534 (Vote Outperform)Underperform Votes: 330 (Vote Underperform)Total Votes: 864MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Short Selling Stocks and Day Traders Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.